$PHIO
Phio Pharmaceuticals Corp

2017 Q2 Form 10-Q Financial Statement

#000119312517166563 Filed on May 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -70.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.100M $1.120M $950.0K
YoY Change 23.6% 17.89% 9.2%
% of Gross Profit
Research & Development $1.329M $1.347M $1.305M
YoY Change -0.75% 3.22% -38.06%
% of Gross Profit
Depreciation & Amortization $20.00K $11.00K $14.00K
YoY Change 0.0% -21.43% -33.33%
% of Gross Profit
Operating Expenses $2.514M $7.081M $2.255M
YoY Change 13.04% 214.01% -24.33%
Operating Profit -$2.514M -$7.081M -$2.245M
YoY Change 13.5% 215.41% -23.79%
Interest Expense $0.00 $0.00 $7.000K
YoY Change -100.0% -100.0% 600.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $14.00K
YoY Change -100.0% -100.0% 1300.0%
Pretax Income -$2.510M -$7.081M -$2.230M
YoY Change 13.57% 217.53% -24.41%
Income Tax -$1.621M
% Of Pretax Income
Net Earnings -$2.514M -$5.460M -$2.231M
YoY Change 13.65% 144.73% -24.24%
Net Earnings / Revenue -22310.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$62.75M -$136.5M -$223.0M
COMMON SHARES
Basic Shares Outstanding 22.13M shares 22.05M shares 65.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.700M $10.21M $7.690M
YoY Change 32.08% 32.77% 16.87%
Cash & Equivalents $7.702M $10.21M $4.192M
Short-Term Investments $3.500M
Other Short-Term Assets $390.0K $180.0K $320.0K
YoY Change -26.42% -43.75% -20.0%
Inventory
Prepaid Expenses $337.0K $125.0K $265.0K
Receivables
Other Receivables
Total Short-Term Assets $8.089M $10.38M $8.007M
YoY Change 27.21% 29.64% 14.7%
LONG-TERM ASSETS
Property, Plant & Equipment $275.0K $105.0K $149.0K
YoY Change 103.7% -29.53% -12.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K $18.00K
YoY Change 0.0% 50.0% 0.0%
Total Long-Term Assets $302.0K $132.0K $167.0K
YoY Change 86.42% -20.96% -11.17%
TOTAL ASSETS
Total Short-Term Assets $8.089M $10.38M $8.007M
Total Long-Term Assets $302.0K $132.0K $167.0K
Total Assets $8.391M $10.51M $8.174M
YoY Change 28.68% 28.6% 14.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $741.0K $672.0K $281.0K
YoY Change 149.49% 139.15% -38.78%
Accrued Expenses $1.713M $1.593M $940.0K
YoY Change 36.39% 69.47% -14.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.454M $2.265M $1.221M
YoY Change 58.02% 85.5% -21.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.454M $2.265M $1.221M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.450M $2.270M $1.220M
YoY Change 58.06% 86.07% -21.79%
SHAREHOLDERS EQUITY
Retained Earnings -$74.07M -$71.56M -$59.34M
YoY Change 20.35% 20.6% 19.08%
Common Stock $2.000K $2.000K $1.000K
YoY Change 100.0% 100.0% -66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.937M $8.247M $6.953M
YoY Change
Total Liabilities & Shareholders Equity $8.391M $10.51M $8.174M
YoY Change 28.68% 28.6% 14.02%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$2.514M -$5.460M -$2.231M
YoY Change 13.65% 144.73% -24.24%
Depreciation, Depletion And Amortization $20.00K $11.00K $14.00K
YoY Change 0.0% -21.43% -33.33%
Cash From Operating Activities -$2.320M -$2.800M -$2.930M
YoY Change 24.73% -4.44% 48.73%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K $2.000K
YoY Change
Acquisitions -$100.0K
YoY Change
Other Investing Activities $0.00 $100.0K $2.000M
YoY Change -100.0% -95.0%
Cash From Investing Activities -$190.0K $100.0K $2.000M
YoY Change -112.67% -95.0% -20100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.320M -2.800M -2.930M
Cash From Investing Activities -190.0K 100.0K 2.000M
Cash From Financing Activities 0.000
Net Change In Cash -2.510M -2.701M -930.0K
YoY Change 597.22% 190.43% -51.56%
FREE CASH FLOW
Cash From Operating Activities -$2.320M -$2.800M -$2.930M
Capital Expenditures -$190.0K $2.000K
Free Cash Flow -$2.130M -$2.802M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22127994 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4192000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2016Q1 rxii Cash And Cash Equivalents And Restricted Cash At Carrying Value
CashAndCashEquivalentsAndRestrictedCashAtCarryingValue
4242000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22045481 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22045481 shares
CY2017Q1 us-gaap Assets
Assets
10512000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
10380000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10205000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
672000
CY2017Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14078241 shares
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79804000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1593000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23100
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10512000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2265000
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
125000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
29.59
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
8247000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.98
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
308055 shares
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71559000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
580785 shares
CY2017Q1 rxii Cash And Cash Equivalents And Restricted Cash At Carrying Value
CashAndCashEquivalentsAndRestrictedCashAtCarryingValue
10255000
CY2015Q4 rxii Cash And Cash Equivalents And Restricted Cash At Carrying Value
CashAndCashEquivalentsAndRestrictedCashAtCarryingValue
5167000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13003179 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13003179 shares
CY2016Q4 us-gaap Assets
Assets
13397000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
13106000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12906000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
917000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73428000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1625000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
150000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13397000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2542000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
150000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
10855000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.29
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66099000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
374446 shares
CY2016Q4 rxii Cash And Cash Equivalents And Restricted Cash At Carrying Value
CashAndCashEquivalentsAndRestrictedCashAtCarryingValue
12956000
CY2017Q1 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
2750371 shares
CY2017Q1 rxii Holdback Percentage
HoldbackPercentage
0.03 pure
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15741140 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
2737000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-32000
CY2017Q1 us-gaap Notes Reduction
NotesReduction
150000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
5460000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5460000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
98000
CY2017Q1 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
5000
CY2017Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-100000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-447000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-25000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5460000
CY2017Q1 us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Three months or less
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1347000
CY2017Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> RXi Pharmaceuticals Corporation (&#x201C;<b>RXi</b>,&#x201D; &#x201C;<b>we</b>,&#x201D; &#x201C;<b>our</b>&#x201D; or the &#x201C;<b>Company</b>&#x201D;) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi <font style="white-space:nowrap">(sd-rxRNA</font><sup style="font-size:85%; vertical-align:top">&#xAE;</sup>) platform and Samcyprone&#x2122; which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company&#x2019;s clinical development programs include <font style="white-space:nowrap">RXI-109,</font> an <font style="white-space:nowrap">sd-rxRNA</font> for the treatment of dermal and ocular scarring, and Samcyprone&#x2122;, a topical immunomodulator, for the treatment of warts. The Company&#x2019;s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas.</p> </div>
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2799000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8423 pure
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0249 pure
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.2301 pure
CY2017Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2990000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.71
CY2017Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2017Q1 dei Trading Symbol
TradingSymbol
RXII
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
226384 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0196 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.51
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
114000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
20045 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8332 pure
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20571143 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
25.75
CY2017Q1 rxii Cash And Cash Equivalents And Restricted Cash Period Increase Decrease
CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease
-2701000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2946908 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
950000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7000
CY2016Q1 us-gaap Revenues
Revenues
10000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-166000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
2255000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-2231000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2000000
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2000000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-882000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-46000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2245000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2925000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8864 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0202 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1670 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0118 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.20
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
294000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7942 pure
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6534846 shares
CY2016Q1 rxii Cash And Cash Equivalents And Restricted Cash Period Increase Decrease
CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease
-925000

Files In Submission

Name View Source Status
0001193125-17-166563-index-headers.html Edgar Link pending
0001193125-17-166563-index.html Edgar Link pending
0001193125-17-166563.txt Edgar Link pending
0001193125-17-166563-xbrl.zip Edgar Link pending
d349103d10q.htm Edgar Link pending
d349103dex311.htm Edgar Link pending
d349103dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20170331.xml Edgar Link completed
rxii-20170331.xsd Edgar Link pending
rxii-20170331_cal.xml Edgar Link unprocessable
rxii-20170331_def.xml Edgar Link unprocessable
rxii-20170331_lab.xml Edgar Link unprocessable
rxii-20170331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending